

## TITLE PAGE

# Rationale and design of the Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) Trial and LIGHT-ACD Trial

### Short Title:

Rationale and design of LIGHT and LIGHT-ACD Trials

### Authors:

Jiali Song, MD; Xiu-Ling Wang, MD; Bin Wang, MD; Yan Gao, MA; Jia-Min Liu, MD; Hai-Bo Zhang, MD; Xi Li, MD, PhD; Jing Li, MD, PhD; Ji-Guang Wang, MD, PhD; Jun Cai, MD, PhD; Jeph Herrin, PhD; Jane Armitage, FRCP, FFPH<sup>#</sup>; Harlan M. Krumholz, MD, SM<sup>#</sup>; Xin Zheng, MD, PhD<sup>#†</sup>; on behalf of the LIGHT Collaborative Group

<sup>#</sup>Joint senior authors

<sup>†</sup>Corresponding authors

### Author Affiliations:

National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China (Song, X.L. Wang, B. Wang, Gao, Liu, Zhang, X. Li, J. Li, Zheng); Hypertension Center, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beijing, China (Cai); The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.G. Wang); Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of

Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LF, UK (Armitage); MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK (Armitage); Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, United States (Krumholz); Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States (Herrin, Krumholz); Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, United States (Krumholz).

**Correspondence:**

Dr. Xin Zheng, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, 167 Beilishi Road, Beijing 100037, People's Republic of China; Tel: +86 10 6086 6719; Email: [xin.zheng@fwoxford.org](mailto:xin.zheng@fwoxford.org)

**Background:** Computerized clinical decision support systems (CDSS) are low-cost, scalable tools with the potential to improve guideline-recommended antihypertensive treatment in primary care. Uncertainty remains about the optimal initial antihypertensive therapy in the settings of real practice.

**Methods:** The Learning Implementation of Guideline-based decision support system for Hypertension Treatment (LIGHT) trial is a pragmatic, cluster-randomized controlled trial of CDSS versus usual care conducted in 100 primary care practices in China. The primary outcome is the proportion of hypertension visits with appropriate (guideline-recommended) antihypertensive treatment. Among patients recruited from primary care practices of the intervention group in the LIGHT trial, we further conducted a sub-study, the LIGHT-ACD trial, to compare the effects of initial antihypertensive therapy by randomizing individual patients to receive different antihypertensive regimens of initial monotherapy or dual therapy. The primary outcome of the sub-study is the absolute change in blood pressure from baseline to 9 months.

**Results:** We hypothesize that the use of CDSS will result in a higher proportion of appropriate antihypertensive treatments being prescribed during visits for hypertension control in the LIGHT trial, and that particular choices of monotherapy or combinations of dual therapy lead to greater blood pressure change in the LIGHT-ACD trial.

**Conclusion:** These nested trials will provide reliable evidence on the effectiveness of CDSS for improving adherence to guidelines for hypertension management in primary care, and data on the effectiveness of different initial antihypertensive regimens for blood pressure reduction.

**Registration number:** LIGHT (NCT03636334) and LIGHT-ACD (NCT03587103).

## 1 INTRODUCTION

2 Hypertension is the leading modifiable risk factor of death globally.<sup>1</sup> Over the past  
3 decades, the number of individuals with hypertension is estimated to have increased  
4 by 90%, with the majority of the increase occurring in low- and middle-income  
5 countries (LMICs).<sup>2</sup> In China, an estimated 244.5 million adults have hypertension,  
6 and only about 15% of these individuals have adequate blood pressure control,  
7 resulting in major health and economic burdens.<sup>3</sup>

8 Improving the performance of primary care providers who play a key role in  
9 managing hypertension, and reducing the heterogeneity of antihypertensive  
10 treatments are public health priorities in China.<sup>4</sup> Despite decade-long efforts to  
11 improve the primary care system,<sup>5</sup> there is still a lack of adequately qualified  
12 providers.<sup>4,6</sup> Moreover, underuse of antihypertensive medications persists.<sup>6</sup>  
13 Traditional strategies, including training sessions, have focused on improving the  
14 performance of providers, but most have only yielded modest effects.<sup>7</sup> Furthermore,  
15 such interventions are often difficult to implement widely because retraining of  
16 providers is resource-intensive.<sup>6</sup> These barriers to adequate management of  
17 hypertension in China have led to calls for the implementation of computerized clinical  
18 decision support system (CDSS) to aid compliance with guidelines.<sup>4,6</sup> Such systems  
19 are characterized by computerized algorithms which generate guideline-based  
20 recommendations, and hence have the potential to improve appropriate medication  
21 prescribing. However, few studies have assessed this effect, especially in  
22 resource-constrained settings. Most studies of CDSS were based on blood pressure

1 levels or target attainment, and had shown mixed results.<sup>8-11</sup> Systematic reviews had  
2 aimed to summarize the literature but the heterogeneity of systems made it difficult to  
3 draw firm conclusions.<sup>12</sup> Understanding whether and to what extent a CDSS causally  
4 affects adherence to guidelines for hypertension management in primary care could  
5 provide important information for policy makers to develop effective strategies for  
6 mitigating the burden of hypertension in China.

7 Equally important to hypertension control is the treatment regimen but uncertainty  
8 exists in the optimal initial antihypertensive therapy, particularly in the settings of real  
9 practice. There are several initial guideline-based treatment options based on  
10 previously published clinical trials or meta-analysis,<sup>13,14</sup> such as thiazide diuretics,  
11 angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, or calcium  
12 channel blockers. The blood pressure lowering effects of these antihypertensive  
13 medication classes are well understood. However, there are differences in  
14 tolerability,<sup>13,15,16</sup> which combinations to use for patients with uncontrolled blood  
15 pressure after initial therapy are also not clear. Assessing the effectiveness and  
16 tolerability of different antihypertensive regimens of initial therapy for blood pressure  
17 reduction may help physicians refine the choice of medication, which is of great  
18 consequence in terms of health outcomes and the cost of patients.<sup>17</sup>

19 Accordingly, we have developed a CDSS for hypertension management and  
20 designed a pragmatic, cluster-randomized controlled trial, the Learning  
21 Implementation of Guideline-based decision support system for Hypertension  
22 Treatment (LIGHT) trial, to assess its effectiveness on improving appropriate

1 antihypertensive treatment in China. In the framework of LIGHT trial, we are also  
2 conducting a sub-study, the LIGHT-ACD trial, to determine the optimal initial therapy  
3 for blood pressure reduction.

4

## 5 **METHODS**

### 6 **Overview of the LIGHT and LIGHT-ACD trials**

7 The LIGHT trial is a pragmatic, parallel-group, multi-stage, cluster-randomized  
8 controlled trial assessing the effectiveness of CDSS-based intervention, with primary  
9 care practices as the unit of randomization. For each stage, we randomize all the sites  
10 to the intervention and control groups based on the data collected during a 3-month  
11 baseline period. The trial's intervention duration is 12 months, including 3 months of  
12 recruitment and 9 months of follow-up. After recruitment, all eligible patients are asked  
13 to come to the clinic for follow-up at least every 3 months (**Figure 1**). The visit interval  
14 is in line with recommendations in the Chinese guideline for the management  
15 of hypertension in primary care<sup>18</sup>. The LIGHT-ACD trial is applied through the CDSS  
16 in the intervention sites of LIGHT trial. This sub-study randomizes patients to various  
17 initial antihypertensive therapies and compares blood pressure changes across these  
18 groups (**Figure 2**).

19 Both trials are being conducted in 100 sites in China. There will be 4 stages in  
20 total, and the intervention of the first stage began on 21 August 2019. All sites will  
21 complete the 9-month follow-up by the beginning of 2022. In the first half of 2020, the  
22 implementation of both trial was affected by the outbreak of COVID-19 in China. We

1 extended the follow-up and recruitment period of the first and second stage of the trial  
2 respectively. By July 2, 2020, twenty-seven sites (including 3701 patients) had been  
3 randomized in the first two stage of the LIGHT trial and 380 participants in the  
4 LIGHT-ACD trial.

5 The LIGHT (NCT03636334) and LIGHT-ACD (NCT03587103) trials are  
6 registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov). The ethics committee of Fuwai Hospital approved  
7 both trials. All sites accepted this ethics approval or obtained local approval by internal  
8 ethics committees as appropriate. Informed consent for implementing the CDSS in  
9 both trials was waived given that CDSS, which provides guideline-based  
10 recommendations, was considered to have minimal risk for the patients. Written  
11 informed consent for participants was acquired for the purpose of sending a text  
12 message as a brief medical record (e.g., blood pressure, prescriptions and follow-up  
13 reminders) after each visit.

14

## 15 **The LIGHT trial**

### 16 ***Site selection***

17 Primary care practices with outpatient clinics for hypertension are eligible if they  
18 have: (1) at least one agent available from each of the four classes of  
19 antihypertensive medications (angiotensin-converting enzyme inhibitors or  
20 angiotensin receptor blockers, beta-blockers, calcium channel blockers, and diuretics);  
21 (2) routine use of an electronic health record (EHR) for hypertension management;  
22 and (3) at least 100 patients with hypertension being routinely seen.

23

1     **Randomization**

2           Primary care practices (clusters) were randomly allocated to the intervention (i.e.,  
3     installation of the CDSS into the EHR) or control arm (usual care) in a 1:1 ratio using  
4     random numbers. Stratified randomization was performed separately for each stage.  
5     The stratification factors include baseline appropriate (guideline-recommended)  
6     antihypertensive treatment rates and site characteristics, including the hospital to  
7     which a primary care practice is affiliated, geographical region, or type of primary care  
8     practice (as appropriate to the stage).

9

10    **Patient recruitment**

11           Local residents aged  $\geq 18$  years with established essential hypertension are  
12    eligible for the LIGHT study if they are taking  $\leq 2$  classes of antihypertensive  
13    medications. Major exclusion criteria include: (1) systolic blood pressure (SBP)  $\geq 180$   
14    mmHg or diastolic blood pressure (DBP)  $\geq 110$  mmHg; (2) history of coronary heart  
15    disease, heart failure, or chronic kidney disease; and (3) intolerance to  $\geq 2$  classes of  
16    antihypertensive medications (**Table 1**). As the visit is the observation unit for the  
17    primary and secondary outcomes, both scheduled and unscheduled visits of eligible  
18    patients for hypertension or other cardiovascular disease are eligible for inclusion in  
19    these outcomes' denominator (**Supplement 1**).

20

21    **Intervention development and testing**

22           The CDSS was integrated into the EHR of the intervention sites and consisted of  
23    three core components: (1) point-of-care decision support for antihypertensive



1 therapy with regard to the class and dose of antihypertensive medication; (2) alerts for  
2 referral, contraindications, and underdose or overdose of antihypertensive medication;  
3 and (3) alerts for re-evaluation of the antihypertensive therapy if a physician does not  
4 follow the CDSS recommendation.

5 The CDSS was developed by a multidisciplinary team including clinicians and  
6 information technology (IT) experts. Clinicians and academics developed the CDSS  
7 algorithm which provides patient-specific medication recommendations and alerts.  
8 The algorithm was developed mainly based on hypertension management guidelines  
9 for primary care in China.<sup>18</sup> Other guidelines from the USA and Europe were also  
10 considered.<sup>19-21</sup>

11 After the algorithm had been finalized, IT experts worked together to translate the  
12 algorithm into computational logic. The CDSS logic was tested using simulated  
13 patient data to trigger each possibility of the algorithm. After internal testing, the CDSS  
14 was provided for clinicians for further validation.

15 We retrieved alerts and medication recommendations of CDSS for the patient  
16 and compared them with the recommendation given by clinicians. The IT experts  
17 were notified when any discrepancies were found so that the programming errors  
18 could be identified. This process was repeated until no errors were observed in all test  
19 cases. The user interface was tested by doctors in two excluded primary care  
20 practices specifically to ensure the usability of CDSS.

21

## 22 ***Data collection, quality control and data management***

1 *Data collection*

2 Sociodemographic characteristics (age, gender, education, and health insurance),  
3 physical measurements (blood pressure, heart rate, waist circumference, height, and  
4 weight), cardiovascular risk factors and co-morbidities, current medications,  
5 medication adherence, prescriptions, information on self-reported home monitoring  
6 blood pressure, and side-effects related to antihypertensive medications of  
7 participants are collected via EHR. Blood pressure is measured with the patient  
8 seated, using the same validated automated sphygmomanometer (Omron  
9 HBP-1300)<sup>22</sup> after at least a 5-minute rest at each visit. Two blood pressure readings  
10 are taken 1–2 minutes apart and the average value is recorded. For primary care  
11 practices in the intervention arm, if doctors do not follow the recommendations of  
12 CDSS, the relevant reasons will be recorded.

13 *Data management*

14 All data are securely transmitted to the central server through automatic  
15 electronic transfer and securely stored in an encrypted and password-protected  
16 database. The database can be accessed only by approved staff members. At the  
17 local sites, all staff members must use their own usernames and passwords to log into  
18 the EHR, which will create an audit trail of all data entered or changed. Data  
19 confidentiality policies on data collection, storage, and analysis have been strictly  
20 imposed in order to ensure the confidentiality of personal information.

21 *Quality control*

22 We developed a web-based platform to monitor real-time project progress and

1 quality, and to provide management support for primary health care practice staff.  
2 On-site monitoring of recruitment, physical measurements, and accuracy of the data  
3 documentation are regularly conducted by trained staff to ensure the quality of data  
4 collection. All automated sphygmomanometers are calibrated annually. In addition, to  
5 ensure the accuracy of the blood pressure value, research staff will randomly audit at  
6 least one blood pressure values documented in the EHR against the recording in the  
7 electronic blood pressure monitor from all sites on a daily basis.

8

## 9 **Outcomes**

10 The primary outcome is the proportion of hypertension visits with appropriate  
11 treatment. Appropriate treatment is defined as the prescription compliant with all the  
12 pre-specified evidence-based recommendations. These recommendations mainly  
13 include titrating or switching treatment for patients with poor blood pressure control,  
14 using a particular antihypertensive medication for patients with specific clinical  
15 indications or without compelling contraindications or intolerance to their use. Detailed  
16 recommendations specifications are shown in **Supplement 2**.

17 The secondary outcomes include the average change in systolic blood pressure,  
18 blood pressure control rate at 9 months, and the proportion of hypertension visits with  
19 acceptable treatment. Acceptable treatment is defined as either appropriate treatment  
20 or non-appropriate treatment with reasons for failing to titrate treatment. Exploratory  
21 outcomes include a composite of cardiac death, non-fatal stroke, and non-fatal  
22 myocardial infarction. (**Table 2**)

1

## 2 ***Statistical analysis***

3 We initially assumed that at least 10 primary care practices are randomized to the  
4 intervention arm and 10 to the control arm, and the baseline appropriate treatment  
5 rate is 55% with maximum type II error of  $\alpha=0.05$ . With 20 practices, assuming a  
6 moderate intra-site correlation of 0.05, a within-patient correlation of 0.1, and a  
7 statistical power of 90%, we needed 3 hypertension visits per patient for 50 patients at  
8 each site in order to detect a 18% absolute difference in appropriate treatment rate  
9 between the two arms.

10 Although we based our initial planning and site recruitment on this sample size  
11 calculation, we currently have 100 sites that are or will be randomized. Under the  
12 same assumptions as above but with 50 intervention and 50 control sites, we will be  
13 able to detect a 4% absolute difference in appropriate treatment rate between arms.

14 The analyses and reporting of the results will follow the Consolidated Standards  
15 of Reporting Trials guidelines for cluster randomized controlled trials.<sup>23</sup> All the  
16 intervention evaluations will be performed on an intention-to-treat basis. Multiple  
17 imputation by chained equations will be used to account for missing values, for both  
18 explanatory and outcome variables.

19 The baseline characteristics of patients will be analyzed to assess cluster  
20 differences between the intervention and control groups. We will summarize  
21 continuous variables as median with interquartile ranges and categorical variables as  
22 frequency with percentage. With all comparative outcomes, absolute differences with

1 95% CIs will be presented and adjusted by patient and site baseline characteristics.  
2 Implementation stages will be treated as strata, with adjustment for calendar time to  
3 account for secular trends. The analysis of both primary and secondary outcomes will  
4 account for the clustering effect using mixed-effects models with primary care practice  
5 as a random effect. The consistency of treatment effects on the primary outcome will  
6 be explored in predefined subgroups, including age, gender, education,  
7 implementation stage, and tertile of cluster-level endpoints. All statistical tests will be  
8 performed using 2-sided tests at the 0.05 level of significance.

9

## 10 **The LIGHT-ACD trial**

### 11 ***Patient recruitment***

12 The LIGHT-ACD trial aims to include all participants in the intervention sites of  
13 the LIGHT trial who are not taking antihypertensive medication or taking only one  
14 medication which is not a beta-blocker and with a SBP  $\geq$  140 mm Hg. Key exclusion  
15 criteria includes diabetes mellitus and intolerance to at least one class of  
16 antihypertensive medications (**Table 1**).

17 Participants in the LIGHT-ACD trial are categorized into 2 subpopulations.  
18 Participants with a SBP of 140–159 mm Hg, and not taking any antihypertensive  
19 medication are categorized as Population 1, the reminder as Population 2.

20

### 21 ***LIGHT-ACD randomization***

22 Populations 1 and 2 are randomized separately. Six three-step protocols are  
23 integrated into the algorithm of CDSS. Population 1 are randomized to receive one of

1 the initial monotherapies of A (angiotensin-converting enzyme inhibitor or angiotensin  
2 receptor blocker), C (calcium channel blocker), or D (diuretics). Subsequently, the  
3 participants initiated with A are randomized to add C or D following protocol  
4 A-AC-ACD or A-AD-ADC, respectively, if necessary, to achieve blood pressure control.  
5 Similar randomization procedures are applied in participants initiated with C or D.  
6 Population 2 are randomized to receive one of the three initial dual therapies of AC,  
7 AD, or CD, and then D, C, or A is added to achieve blood pressure control,  
8 respectively (**Figure 2**). Minimized randomization is used to ensure balance by age,  
9 gender and education level among the three arms of the two populations. Neither  
10 participants nor physicians are blinded to treatment allocation but the allocation is  
11 concealed within the CDSS.

12

### 13 ***LIGHT-ACD treatment***

14 The assignment of treatment is presented as the medication recommendation  
15 (class and dose) by the CDSS. The specific agent within each class is at the  
16 physician's discretion based on the available medications at the primary care  
17 practices.

18 For each case, the titration of antihypertensive medications is performed  
19 automatically by CDSS according to the assigned treatment protocol. Participants  
20 who are unable to follow their protocols because of a new onset of complications (e.g.,  
21 coronary heart disease) receive usual care. Those who are unable to follow their  
22 regimen because of medication intolerance, are assigned to a new protocols

1 automatically by CDSS.

2

### 3 ***LIGHT-ACD outcomes***

4 The primary outcome is the change in blood pressure from baseline to 9 months  
5 of different regimens of initial therapy. Secondary outcomes include the proportion of  
6 individuals with SBP <140 mm Hg and DBP <90 mm Hg at 9 months; the proportion of  
7 individuals with SBP <160 mm Hg and DBP <100 mm Hg at 9 months; the proportion  
8 of individuals who received monotherapy (only in Population 1), dual therapy, triple  
9 therapy, and referral at 9 months; the proportion of individuals reported to have  
10 antihypertensive drug related side-effects; and the proportion of individuals  
11 transferred to usual care for any reasons. The exploratory outcome is the change in  
12 blood pressure from baseline to 9 months of different protocols. (**Table 2**)

13

### 14 ***LIGHT-ACD statistical analysis***

15 We assume approximately 25% of the LIGHT intervention patients are in  
16 Population 1 and 75% in Population 2, with an 80% follow-up rate for the primary  
17 outcome. For each population, we estimate the detectable difference in SBP between  
18 treatment groups across a similar range of the intervention participants and statistical  
19 power. We assume that the standard deviation in SBP is  $\sigma=10$  mmHg, and that the  
20 within-patient SBP correlation is  $R^2=0.2$  with a maximum type II error that is  
21 Sidak-corrected for three comparisons,  $\alpha=0.017$ .<sup>24</sup> With 100 LIGHT sites, we estimate  
22 at least 2100 eligible LIGHT-ACD participants overall with complete follow-up. Under

1 these assumptions, we estimate that for Population 1 comparisons we will have 80%  
2 power to detect a difference of 3.5 mm Hg in SBP, and for Population 2 comparisons,  
3 we have 80% power to detect a difference of 2 mm Hg in SBP.

4 All the intervention evaluations will be performed on an intention-to-treat basis.  
5 Multiple imputation by chained equations will be used to account for missing values,  
6 for both explanatory and outcome variables.

7 We will use frequencies with percentages to describe categorical variables and  
8 means with SDs to describe continuous variables unless skewed, which we present  
9 as medians and interquartile ranges. The differences between the three groups will be  
10 assessed either by univariate analyses of variance (ANOVA) or by  $\chi^2$  tests. For  
11 pairwise testing of primary outcomes, multiple Student t tests or Mann-Whitney U  
12 tests will be used; P values will be adjusted for multiple comparisons by using the  
13 Sidak method. As secondary analyses, the primary end points will be adjusted for  
14 baseline blood pressure values by analysis of covariance (ANCOVA). For secondary  
15 outcomes, log-binomial regression will be used to compare groups and calculate  
16 relative risk of outcomes at 9 months.

17 Additionally, we will perform pre-specified subgroup analyses of outcomes by age,  
18 sex, education, smoking status, and tertile of baseline blood pressure.

19

## 20 **DISCUSSION**

21 The LIGHT trial, to the best of our knowledge, is the largest pragmatic  
22 randomized trial showing the feasibility and effectiveness of a new model of delivering



1 high-quality care for hypertension in primary care settings. Moreover, by adopting a  
2 streamlined study design, we embed a patient-randomized controlled trial  
3 (LIGHT-ACD study) into a cluster-randomized trial through an algorithm-enabled  
4 CDSS tool, representing a contemporary paradigm of clinical research to improve the  
5 efficiency of the trial and accelerate the generation of evidence through electronic  
6 health systems, standardized treatment regimens, and decision support systems.

7 Our studies have several strengths. First, we developed a usable CDSS, which  
8 can seamlessly integrate into clinical routine workflow and provide tailored  
9 antihypertensive recommendations at the point of care. These features are highly  
10 correlated with effective CDSS for improving process of care and patient  
11 outcomes.<sup>25,26</sup> The use of a CDSS in primary care may reduce the heterogeneity of  
12 care due to the lack of qualified doctors for hypertension management in China. As  
13 recommendations and alerts of CDSS are generated automatically by the built-in  
14 algorithm, which was developed based on current guidelines, this approach can thus  
15 assist primary care doctors, even those with less training, in making informed and  
16 evidence-based medical decisions.

17 Second, we have built a streamlined framework for a clinical trial that enables us  
18 to compare the effectiveness of several guideline-based initial antihypertensive  
19 therapies. Earlier randomized clinical trials such as the ALLHAT<sup>14</sup> and  
20 ACCOMPLISH<sup>27</sup> trials, had provided a direct comparison among several  
21 monotherapies or dual therapies. In contrast with these standalone trials, the conduct  
22 of the LIGHT-ACD trial is embedded into the existing framework of the LIGHT trial. We

1 have incorporated a series of stepped treatment protocols into the CDSS, whereby  
2 the randomized allocation of recommended medication can be performed  
3 automatically by following the algorithm-consistent order at each encounter where  
4 decision support is delivered.<sup>28</sup> While assessing the effectiveness of CDSS, we can  
5 also compare the effectiveness of common initial antihypertensive monotherapies or  
6 dual therapies in an unobtrusive manner.<sup>16,27,29,30</sup>

7 Third, the pragmatic design of both trials, are built on the infrastructure of the  
8 electronic health records already routinely used in primary care practices. Although  
9 traditional explanatory trials remain a key tool for demonstrating the efficacy of  
10 intervention/treatment in highly controlled settings, the pragmatic design can deliver  
11 real-world effectiveness with greater external validity.<sup>31,32</sup> In contrast to trials with  
12 study-specific visits, the enrollment and follow-up of patients, and the collection of  
13 outcome data in our trial are incorporated into routine clinical practice. Moreover, the  
14 exclusion criteria are kept to a minimum to enroll a diverse spectrum of the population.  
15 These considerations improve the efficiency of trials and enhance generalizability of  
16 the study results.<sup>32</sup>

17 Fourth, the two studies are further distinguished by their efforts to build a learning  
18 decision support tool. Apart from basic functions of CDSS such as medication  
19 recommendation and alerts, the tool itself can generate new knowledge in terms of  
20 the effectiveness of treatment strategies embedded in the CDSS from the ongoing  
21 delivery of care. These study results, in turn, can be used to adaptively improve CDSS  
22 by shifting the randomization ratio of stepped antihypertensive protocols toward the

1 more effective group.<sup>33</sup> The updated CDSS can also be iteratively implemented,  
2 tested, and improved.

3 Our study has some potential limitations. First, our study outcomes are focused  
4 on surrogate outcomes instead of clinical outcomes such as death or vascular events.  
5 To examine the effectiveness on clinical events, a much larger and longer trial would  
6 be required. However, it is expected that improvements in blood pressure control over  
7 time would favorably affect clinical outcomes. Second, given the nature of CDSS,  
8 which delivers its recommendation directly to physicians, blinding was not feasible in  
9 both studies. We minimized the potential bias by using objective measures as primary  
10 and secondary outcomes. Third, due to the limited timeframe of the study, an  
11 extended follow-up period was not included following the 12-month intervention to  
12 measure persistence of effects after the intervention ceases.

13 In conclusion, these two trials will provide reliable evidence regarding the  
14 effectiveness of CDSS on improving adherence to guidelines for hypertension  
15 management in primary care, and data on the effectiveness of different initial  
16 antihypertensive regimens for blood pressure reduction in the real-world setting.

17

## 1 REFERENCES

- 2 1. Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national  
3 comparative risk assessment of 84 behavioural, environmental and  
4 occupational, and metabolic risks or clusters of risks for 195 countries and  
5 territories, 1990-2017: a systematic analysis for the Global Burden of Disease  
6 Study 2017. *Lancet (London, England)*. 2018;392(10159):1923-1994.
- 7 2. Bin Zhou, James Bentham, Cesare Mariachiara D, et al. Worldwide trends in  
8 blood pressure from 1975 to 2015: a pooled analysis of 1479  
9 population-based measurement studies with 19.1 million participants. *The*  
10 *Lancet*. 2017;389(10064):37-55.
- 11 3. Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China. *Circulation*.  
12 2018;137(22):2344-2356.
- 13 4. Li X, Krumholz HM, Yip W, et al. Quality of primary health care in China:  
14 challenges and recommendations. *The Lancet*. 2020;395(10239):1802-1812.
- 15 5. Chen Z. Launch of the health-care reform plan in China. *Lancet (London,*  
16 *England)*. 2009;373(9672):1322.
- 17 6. Liang W, Binns CW, Lee AH. Computerised clinical decision support in rural  
18 China. *The Lancet*. 2009;373(9657):30.
- 19 7. Rowe AK, Rowe SY, Peters DH, Holloway KA, Chalker J, Ross-Degnan D.  
20 Effectiveness of strategies to improve health-care provider practices in  
21 low-income and middle-income countries: a systematic review. *The Lancet*  
22 *Global Health*. 2018;6(11):e1163-e1175.

- 1 8. Montgomery AA. Evaluation of computer based clinical decision support  
2 system and risk chart for management of hypertension in primary care:  
3 randomised controlled trial. *BMJ (Clinical research ed)*.  
4 2000;320(7236):686-690.
- 5 9. Bosworth H, Olsen M, Dudley T, et al. Patient education and provider decision  
6 support to control blood pressure in primary care: a cluster randomized trial.  
7 *Am Heart J*. 2009;157(3):450-456.
- 8 10. Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control  
9 through provider education, provider alerts, and patient education: a cluster  
10 randomized trial. *Annals of internal medicine*. 2006;145(3):165-175.
- 11 11. Hicks LS, Sequist TD, Ayanian JZ, et al. Impact of computerized decision  
12 support on blood pressure management and control: a randomized controlled  
13 trial. *Journal of general internal medicine*. 2008;23(4):429-441.
- 14 12. Groenof TKJ, Asselbergs FW, Groenwold RHH, Grobbee DE, Visseren FLJ,  
15 Bots ML. The effect of computerized decision support systems on  
16 cardiovascular risk factors: a systematic review and meta-analysis. *BMC*  
17 *Medical Informatics and Decision Making*. 2019;19(1).
- 18 13. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. *Cochrane*  
19 *Database of Systematic Reviews*. 2018.
- 20 14. The Allhat O, Coordinators For The Allhat Collaborative Research G. Major  
21 Outcomes in High-Risk Hypertensive Patients Randomized to  
22 Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs

- 1 Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart  
2 Attack Trial (ALLHAT). *JAMA: The Journal of the American Medical*  
3 *Association*. 2002;288(23):2981-2997.
- 4 15. Law MR. Value of low dose combination treatment with blood pressure  
5 lowering drugs: analysis of 354 randomised trials. *BMJ (Clinical research ed)*.  
6 2003;326(7404):1427-1420.
- 7 16. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative  
8 effectiveness and safety of first-line antihypertensive drug classes: a  
9 systematic, multinational, large-scale analysis. *The Lancet*.  
10 2019;394(10211):1816-1826.
- 11 17. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical  
12 and public health advisory from The National High Blood Pressure Education  
13 Program. *Jama*. 2002;288(15):1882-1888.
- 14 18. Office for Management of Hypertension in Primary Health Care NEPHSP.  
15 National Hypertension Prevention and Management Guidelines for Primary  
16 Health Care. *Chinese Circulation Journal*. 2017(11).
- 17 19. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the  
18 management of high blood pressure in adults: report from the panel members  
19 appointed to the Eighth Joint National Committee (JNC 8). *Jama*.  
20 2014;311(5):507-520.
- 21 20. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the  
22 management of arterial hypertension: the Task Force for the Management of

- 1 Arterial Hypertension of the European Society of Hypertension (ESH) and of  
2 the European Society of Cardiology (ESC). *Eur Heart J*.  
3 2013;34(28):2159-2219.
- 4 21. National Collaborating Centre for Chronic C. National Institute for Health and  
5 Clinical Excellence: Guidance. In: *Hypertension: Management in Adults in*  
6 *Primary Care: Pharmacological Update*. London: Royal College of Physicians  
7 (UK); Royal College of Physicians of London.; 2006.
- 8 22. Meng L, Zhao D, Pan Y, et al. Validation of Omron HBP-1300 professional  
9 blood pressure monitor based on auscultation in children and adults. *BMC*  
10 *Cardiovasc Disord*. 2016.
- 11 23. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement:  
12 extension to cluster randomised trials. *Bmj*. 2012;345:e5661.
- 13 24. ZK. Š. Rectangular Confidence Regions for the Means of Multivariate Normal  
14 Distributions. *Journal of the American Statistical Association*.  
15 1967;62:626-633.
- 16 25. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice  
17 using clinical decision support systems: a systematic review of trials to identify  
18 features critical to success. *BMJ*. 2005.
- 19 26. Bright TJ, Wong A, Dhurjati R, et al. Effect of clinical decision-support systems:  
20 a systematic review. *Annals of internal medicine*. 2012;157(1):29-43.
- 21 27. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus Amlodipine or  
22 Hydrochlorothiazide for Hypertension in High-Risk Patients. *New England*

- 1            *Journal of Medicine*. 2008;359(23):2417-2428.
- 2    28.    Frieden TR, King SMC, Wright JS. Protocol-Based Treatment of Hypertension.
- 3            *JAMA*. 2014;311(1):21.
- 4    29.    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at
- 5            high cardiovascular risk treated with regimens based on valsartan or
- 6            amlodipine: the VALUE randomised trial. *The Lancet*.
- 7            2004;363(9426):2022-2031.
- 8    30.    Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular
- 9            events with calcium channel blocker-based combination therapies in patients
- 10           with hypertension: a randomized controlled trial. *Journal of hypertension*.
- 11           2011;29(8):1649-1659.
- 12    31.    Ford I, Norrie J. Pragmatic Trials. *New England Journal of Medicine*.
- 13           2016;375(5):454-463.
- 14    32.    Mentz RJ, Hernandez AF, Berdan LG, et al. Good Clinical Practice Guidance
- 15           and Pragmatic Clinical Trials. *Circulation*. 2016;133(9):872-880.
- 16    33.    Horwitz LI, Kuznetsova M, Jones SA. Creating a Learning Health System
- 17           through Rapid-Cycle, Randomized Testing. 2019;381(12):1175-1179.
- 18



## **ACKNOWLEDGMENTS**

We appreciate the steering committee member of the study: Robert Clarke from University of Oxford, Sharon-Lise T. Normand from the Harvard T.H. Chan School of Public Health, Frederick A. Masoudi from University of Colorado School of Medicine, Songtao Tang from the Community Health Center of Liaobu County, Wenjun Ma from the Fuwai Hospital, and Jian Xu from the Center for Chronic Disease Control of Shenzhen for their support and advice. We thank Lawrence J. Fine and George A. Mensah from National Institutes of Health for their contributions in study design. We appreciate the multiple contributions made by study teams at the National Clinical Research Center of Cardiovascular Diseases in the realms of study design and operation, particularly site management and coordination by Bo Gu, Yilan Ge, Fuyu Jing, Lei Bi, Huijun Jin, Teng Li, and Liyuan Sui, and IT development and maintenance by Shuyang Hua and Mengnan Zhu. We thank the local sites in the collaborative network for their support and data collection.

## **CONTRIBUTORS**

HMK, JA, and XZ designed the study. XZ acted as the principle investigator to take responsibility for all respect of the study. JS, HMK, JA, and XZ conceived of this article. JS wrote the manuscript with further contributions from XZ, JA, HMK, JH, JW, JC, JL, XL, HZ, JL, BW, XW and YG. JH calculated the sample size and provided advice in randomization method of the study. YG performed daily data monitoring and completed all the statistical analysis. XZ, LJ, HZ, JS, XW, and BW developed the

algorithm of the CDSS. All authors contributed to critical revisions and approved the final version of the article.

## **PATIENT AND PUBLIC INVOLVEMENT**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

## **FUNDING SOURCES**

This project was supported by the CAMS Innovation Fund for Medical Science (2016-I2M-1-006) and the 111 Project (B16005) from the Ministry of Education of China.

## **CONFLICTS OF INTEREST**

Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the US Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in


Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin/Baughman Law Firm for work related to the Cook IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data management company. Dr. Jing Li discloses that she is a recipient of research grants from the government of China, through Fuwai Hospital, for research to improve the management of hypertension and blood lipids, and to improve care quality and patient outcomes of cardiovascular disease; is a recipient of research agreements with Amgen, through National Center for Cardiovascular Diseases (NCCD) and Fuwai Hospital, for a multi-centre trial to assess the efficacy and safety of Omecamtiv Mecarbil, and for dyslipidemic patient registration; is a recipient of a research agreement with Sanofi, through Fuwai Hospital, for a multi-centre trial on the effects of sotagliflozin; is a recipient of a research agreement with University of Oxford, through Fuwai Hospital, for a multi-centre trial of empagliflozin; and was a recipient of a research agreement, through NCCD, from AstraZeneca for clinical research methods training.

## **FIGURE LEGEND**


**Figure 1.** Overview of the multi-stage design of the LIGHT trial

**Figure 2.** Infrastructure of the LIGHT and LIGHT-ACD trials

**Figure 1. Overview of the multi-stage design of the LIGHT trial**



**Figure 2. Infrastructure of the LIGHT and LIGHT-ACD trials**



Population-1: Participants with systolic blood pressure (SBP) of 140–159 mm Hg, and were not taking any antihypertensive medication.

Population-2: Participants with SBP  $\geq$ 160 mm Hg and were not taking any antihypertensive medication or taking one antihypertensive medication which was not beta-blocker, or those with SBP 140–159 mm Hg and were taking one antihypertensive medication which was not beta-blocker.

A: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; C: calcium channel blocker; D: diuretic.

**Table 1. Inclusion and exclusion criteria of participants for LIGHT and LIGHT-ACD trials**

Criteria	LIGHT*	LIGHT-ACD#
<b>Inclusion</b>	Local residents aged ≥18 years diagnosed with essential hypertension	Participants from intervention sites of LIGHT study with systolic blood pressure ≥140 mm Hg at the screening visit
	Taking ≤2 classes of antihypertensive medications	Not taking antihypertensive medication or taking only one which was not beta-blocker
<b>Exclusion</b>	Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg at the screening visit	Known/diagnosed diabetes mellitus
	History of coronary heart disease <sup>†</sup> , heart failure, and chronic kidney disease	Intolerance to ≥1 class of antihypertensive medications
	Intolerance to ≥2 classes of antihypertensive medications	Home blood pressure (if available) below 135/85 mm Hg
	Serious medical conditions (e.g., malignant cancer and hepatic dysfunction)	
	Currently in an acute episode of disease	
	Currently pregnant or breastfeeding, or planning a pregnant or breastfeeding during the study	
	Cognitive or communication disorders	

\*Participants who were not eligible for the LIGHT study at the first screening visit were re-assessed for eligibility at the subsequent visits until the end of recruitment.

#Participants who were not eligible for the LIGHT-ACD study at the first screening visit would not be re-assessed for eligibility at the subsequent visits.

<sup>†</sup> Including angina, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, >50% stenosis of coronary artery,

or positive stress test



**Table 2. Outcomes of LIGHT and LIGHT-ACD studies**

<b>Outcomes</b>	<b>LIGHT</b>	<b>LIGHT-ACD</b>
<b>Primary</b>	Appropriate treatment rate among all post-randomization hypertension visits	Absolute change in blood pressure at 9 months of different regimens of initial therapy
<b>Secondary</b>	Absolute change of systolic blood pressure at 9 months	Proportion of individuals with SBP <140 mm Hg and DBP <90 mm Hg at 9 months
	Blood pressure control rate at 9 months	Proportion of individuals with SBP <160 mm Hg and DBP <100 mm Hg at 9 months
	Acceptable treatment rate among all post-randomization hypertension visits	Proportion of individuals who received monotherapy*, dual therapy, triple therapy, and referral at 9 months
		Proportion of individuals with antihypertensive drug side-effects
		Proportion of individuals transferred to usual care for any reason
<b>Exploratory</b>	A composite of cardiac death, non-fatal stroke, and non-fatal myocardial infarction	Absolute change in blood pressure at 9 months of different protocols*

SBP, systolic blood pressure; DBP, diastolic blood pressure.

Primary and secondary outcomes of LIGHT-ACD were assessed among initiating therapies; exploratory outcomes of LIGHT-ACD were assessed among protocols.

\*Only assessed in Population 1, who are not currently taking any antihypertensive medication with systolic blood pressure 140–159 mm Hg, and initiated with monotherapies